Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tempest Therapeutics

< Previous 1 2 Next >
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Year End 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Adopts Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the Jefferies Global Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Year End 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.